What are BridgeBio Pharma's total assets?

BridgeBio Pharma (BBIO) holds $1.4B in total assets, up 55.5% year over year.

How much debt does BridgeBio Pharma have?

BridgeBio Pharma carries $3.3B in total debt against -$2.3B of shareholders' equity, a debt-to-equity ratio of 1.97.

How much cash does BridgeBio Pharma have?

BridgeBio Pharma holds $882.0M in cash and equivalents.

Can BridgeBio Pharma cover its short-term obligations?

Its current ratio is 1.52 — current assets exceed current liabilities.

Where does BridgeBio Pharma's balance sheet data come from?

Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

BridgeBio Pharma BBIO Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$170.49M-75.0%	$683.24M+81.7%	$375.94M-0.2%	$376.69M-4.3%
Short-term investments	$17.36M—	$0—	$0-100%	$51.58M-86.9%
Restricted cash	——	$126K-99.2%	$16.65M-56.1%	$37.93M+21,329%
Accounts receivable, net	$139.44M+2,853%	$4.72M+170%	$1.75M+146%	-$3.79M—
Inventories	$73.51M—	$0—	$0—	——
Raw materials	$15M—	——	——	——
Work in process	$6.1M—	——	——	——
Finished goods	$6.51M—	——	——	——
Prepaid expenses and other current assets	$192.06M+48.0%	$129.74M+40.1%	$92.58M-19.0%	$114.36M-1.8%
Total current assets	$797.75M+10.7%	$720.69M+50.9%	$477.59M-13.0%	$548.85M-38.3%
Property and equipment, net	$5.37M-23.5%	$7.01M-40.7%	$11.82M-18.9%	$14.57M-51.5%
Accumulated depreciation	$11.32M+32.1%	$8.57M—	——	——
Operating lease right-of-use assets	$8.15M+41.3%	$5.77M-28.2%	$8.03M-24.8%	$10.68M-32.9%
Intangible assets, net	$28.08M+17.3%	$23.93M-9.1%	$26.32M-8.3%	$28.71M-36.1%
Other non-current assets	$16.71M-8.2%	$18.2M-19.6%	$22.63M+11.9%	$20.22M-38.8%
Equity method investments	$79.97M-44.4%	$143.75M—	$0—	——
Total assets	$936.03M+1.8%	$919.34M+68.3%	$546.38M-12.3%	$623.04M-38.5%
Accounts payable	$108.59M+137%	$45.84M+98.6%	$23.08M-43.2%	$40.62M-28.2%
Accrued expenses	$76.7M+31.5%	$58.33M+1.7%	$57.37M+83.5%	$31.26M-15.6%
Deferred revenue	$7.19M-50.8%	$14.6M+292%	$3.73M-54.3%	$8.16M—
Current portion of long-term debt	——	——	——	——
Operating lease liabilities, current	$6.19M+37.4%	$4.51M+9.2%	$4.13M+12.3%	$3.68M-25.6%
Contract liabilities	$13.08M-23.5%	$17.1M—	——	——
Accrued interest	$14.41M+30.3%	$11.06M—	——	——
Derivative liabilities	$21.44M—	——	——	——
Total current liabilities	$287.97M+86.5%	$154.4M+7.3%	$143.84M+18.5%	$121.43M-10.1%
Long-term debt	——	$437.34M-2.0%	$446.45M+3.6%	$430.99M+0.1%
Operating lease liabilities, non-current	$3.81M-18.8%	$4.7M-47.7%	$8.98M-26.8%	$12.27M-29.6%
Operating Lease Liabilities (Total)	$10M+8.7%	$9.2M-29.8%	$13.11M-17.8%	$15.95M-28.7%
Other non-current liabilities	$244K-14.7%	$286K-94.9%	$5.63M-78.9%	$26.64M+20.7%
Total liabilities	$3.01B+26.7%	$2.38B+25.8%	$1.89B+1.1%	$1.87B-0.6%
Preferred stock	$0—	$0—	——	——
Common stock	500M+255,002%	196K+8.3%	181K+15.3%	157K+1.9%
Additional paid-in capital	$2.06B+8.1%	$1.9B+28.5%	$1.48B+57.8%	$938.7M+11.5%
Retained earnings	-$3.82B-23.4%	-$3.1B-20.9%	-$2.56B-33.5%	-$1.92B-33.5%
Accumulated other comprehensive income (loss)	$12K+50.0%	$8K-74.2%	$31K+109%	-$328K-148%
Treasury stock	$323.28M+17.6%	$275M0.0%	$275M0.0%	$275M0.0%
Redeemable noncontrolling interests	-$570K-501%	$142K-70.3%	$478K—	——
Noncontrolling interests	$10.6M+4.4%	$10.15M-9.7%	$11.24M-0.3%	$11.28M+231%
Total stockholders' equity	-$2.09B-42.1%	-$1.47B-8.4%	-$1.35B-7.9%	-$1.25B-44.1%
Total liabilities and stockholders' equity	$936.03M+1.8%	$919.34M+68.3%	$546.38M-12.3%	$623.04M-38.5%
Available-for-Sale Debt Securities - Amortized Cost	$17.36M—	——	——	——
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	$572.14M-16.3%	$683.24M+73.1%	$394.73M—	——
Cash, Cash Equivalents, and Marketable Securities	$17.36M—	——	——	——
Available For Sale Securities Debt Securities Current	$17.36M—	$0—	——	——
Other Inventory, Net	$857K—	——	——	——
Deferred Tax Assets and Other Non-Current Assets	$16.71M-8.2%	$18.2M-19.6%	$22.63M+11.9%	$20.22M-38.8%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five)	——	——	——	——
Finite Lived Intangible Assets - Gross	$39.4M+21.2%	$32.5M—	——	——
Investments - Amortized Cost Basis	$17.36M—	——	——	——
Net Investment in Lease	$8.15M+41.3%	$5.77M-28.2%	$8.03M-24.8%	$10.68M-32.9%
Intangible assets — net	$28.08M+17.3%	$23.93M—	——	——
Other intangible assets—net	$28.08M+17.3%	$23.93M-9.1%	$26.32M-8.3%	$28.71M-36.1%
Operating lease right-of-use assets	$8.15M+41.3%	$5.77M-28.2%	$8.03M-24.8%	$10.68M-32.9%
Other non-current assets	$16.71M-8.2%	$18.2M-19.6%	$22.63M+11.9%	$20.22M-38.8%
Operating Lease Right-of-Use Assets in Other Assets	$8.15M+41.3%	$5.77M-28.2%	$8.03M-24.8%	$10.68M-32.9%
Software and Technology Licenses, Net	$16.71M-8.2%	$18.2M-19.6%	$22.63M+11.9%	$20.22M-38.8%
Accrued Manufacturing Costs	$76.7M+31.5%	$58.33M+1.7%	$57.37M+83.5%	$31.26M-15.6%
Accrued Progress Collections and Price Adjustments	$13.08M-23.5%	$17.1M—	——	——
Accrued research and development liabilities	$41.44M+20.9%	$34.27M+15.1%	$29.77M-25.2%	$39.8M-9.8%
Compensation and benefits	$76.7M+31.5%	$58.33M+1.7%	$57.37M+83.5%	$31.26M-15.6%
Other accrued liabilities	$120.22M+264%	$33.07M—	——	——
Derivative Liabilities - Fair Value	$21.44M—	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Professional Service Fees Payable	$3.67M-0.2%	$3.67M—	——	$1.79M-73.6%
Contract Liabilities, Non-Current	$13.08M-23.5%	$17.1M—	——	——
Debt Maturity - 2024	——	——	——	——
Debt Maturity - 2027	——	——	——	——
Debt Maturity - Thereafter	——	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	$57.8M—	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2029 (Lessee)	——	——	——	——
Lease Liability Payments - Due After Year Five	——	——	——	——
Operating Lease Liability Payments - Thereafter (Lessee)	——	——	——	——
Deferred revenue, net of current portion	$13.08M-23.5%	$17.1M—	——	——
Total debt	$10M-97.8%	$446.54M-2.8%	$459.55M+2.8%	$446.94M-1.7%
Common Stock Par Value Per Share	$0.000.0%	$0.00—	——	——
Common Stock Shares Issued	202.4M+3.1%	196.2M—	——	——
Convertible Preferred Stock Authorized Shares	25M0.0%	25M—	——	——
Convertible Preferred Stock Issued Shares	0—	0—	——	——
Convertible Preferred Stock Outstanding Shares	0—	0—	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$202K+3.1%	$196K+8.3%	$181K+15.3%	$157K+1.9%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.00—	——	——
Unrealized Gains on Investments	$4K—	——	——	——
Unrealized Losses on Investments (Before Tax)	$0—	——	——	——
Cumulative Cost Basis	$17.36M—	——	——	——
Accrued commercial	$35.77M+218%	$11.27M—	——	——
Professional service fees	$3.67M-0.2%	$3.67M—	——	$1.79M-73.6%
Accrued rebates and other related costs	$45.91M+21,761%	$210K—	——	——
Aggregate minimum commitment	——	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$0—	——	——	——
Gross Unrealized Gains	$4K—	——	——	——
Total	$17.36M—	——	——	——
Available for sale investments	$17.36M—	——	——	——
Carrying value of deferred royalty obligations, net	$891.39M—	——	——	——
Cash and cash equivalents, end of period	$572.14M-16.3%	$683.24M+73.1%	$394.73M—	——
Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Current, Before Tax	$12K—	——	——	——
Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Current, Before Tax	$0—	——	——	——
Cash Equivalents And Debt Securities, Available-for-Sale, Fair Value Disclosure	$187.86M—	——	——	——
Cash Equivalents, at Carrying Value And Debt Securities, Available-For-Sale, Amortized Cost	$187.85M—	——	——	——
Unrealized Gains	$8K0.0%	$8K—	——	——
Cash Equivalents Unrealized Losses	$0—	$0—	——	——
Common stock, par value (in dollars per share)	$00.0%	$0—	——	——
Common stock, shares authorized (in shares)	$500M0.0%	$500M—	——	——
Common stock, shares issued (in shares)	$202.37M+3.1%	$196.24M—	——	——
Common Stock, Shares, Outstanding	$194.77M+2.5%	$190.04M—	——	——
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$57.8M—	——	——	——
Deferred royalty obligations, net	$855.03M+78.5%	$479.09M—	$0—	——
Estimated fair value of deferred royalty obligation under funding agreement, net embedded derivative liability	$565.5M+26.8%	$446M—	——	——
Deferred royalty obligations, current portion	$11.22M+7,692%	$144K—	——	——
Equity method investments (Note 11)	$79.97M-44.4%	$143.75M—	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$11.32M+32.1%	$8.57M—	——	——
2028	——	——	——	——
2030	——	——	——	——
2031	——	——	——	——
Remainder of 2026	——	——	——	——
2027	——	——	——	——
2029	——	——	——	——
Finite Lived Intangible Assets Amortization Expense After Year Five	——	——	——	——
Gross Carrying Amount	$39.4M+21.2%	$32.5M—	——	——
Raw materials	$15M—	——	——	——
Lessee Operating Lease Liability Payments Due	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
2028	——	——	——	——
2029	——	——	——	——
2029	——	——	——	——
2030	——	——	——	——
Thereafter	——	——	——	——
2027	——	——	——	——
Remainder of 2026	——	——	——	——
Long-Term Debt, Maturity, Less Amounts Representing Interest	——	——	——	——
Long-Term Debt, Maturity, Total Principal Amount	——	——	——	——
Noncontrolling interests in subsidiaries	$10.6M+4.4%	$10.15M-9.7%	$11.24M-0.3%	$11.28M+231%
Other accrued liabilities	$9.24M+80.3%	$5.13M—	——	$25.19M-16.8%
Accrued Amount, Cash or stock at our sole discretion	——	——	——	——
Accrued Amount, Cash	——	——	——	——
Accrued Amount, Stock	——	——	——	——
Potential Milestone Accrued Settlement Amount	——	——	——	——
Potential Fixed Monetary Amount, Cash	——	——	——	——
Potential Fixed Monetary Amount, Stock	——	——	——	——
Potential Fixed Monetary Amount, Cash or stock at our sole discretion	——	——	——	——
Potential Milestone Fixed Monetary Settlement Amount	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$0—	——	——
Preferred Stock, Shares Authorized	$25M0.0%	$25M—	——	——
Preferred Stock, Shares Issued	$0—	$0—	——	——
Preferred Stock, Shares Outstanding	$0—	$0—	——	——
Redeemable noncontrolling interests in subsidiaries	-$570K-501%	$142K-70.3%	$478K—	——
Maximum amount of stock remaining eligible to be sold	——	——	——	——
Redeemable convertible noncontrolling interests	-$570K-501%	$142K—	——	——
Treasury stock, shares (in shares)	$7.6M+22.7%	$6.19M—	——	——
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about BridgeBio Pharma.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are BridgeBio Pharma's total assets?: BridgeBio Pharma (BBIO) holds $1.4B in total assets, up 55.5% year over year.
How much debt does BridgeBio Pharma have?: BridgeBio Pharma carries $3.3B in total debt against -$2.3B of shareholders' equity, a debt-to-equity ratio of 1.97.
How much cash does BridgeBio Pharma have?: BridgeBio Pharma holds $882.0M in cash and equivalents.
Can BridgeBio Pharma cover its short-term obligations?: Its current ratio is 1.52 — current assets exceed current liabilities.
Where does BridgeBio Pharma's balance sheet data come from?: Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.